Ovarian Cancer
News and reporting on ovarian cancer.
Genoox, Aspira Women's Health Partner to Develop New MDx Technologies
The firms seek to apply AI and machine learning to improve diagnosis and treatment of conditions including ovarian and pelvic diseases.
Newly Combined Finnish Firm Developing POC Instrument Integrating Molecular, Immunoassay Testing
Premium
The companies plan to combine testing for infectious diseases and cancers in one multiplex instrument targeted toward decentralized settings.
Qiagen, OncXerna Therapeutics Ink Companion Dx Development, Technology-Licensing Deal
The partners will develop an NGS companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
The company is developing tests for ovarian mass monitoring and endometriosis that it hopes will expand its addressable market beyond that targeted by OVA1.